Topotecan: 7 agencies, 2006–2020
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused topotecan: all 13 decisive outcomes across 6 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 14.1 years separate the first record, 21 Jun 2006 at HAS (France), from the most recent, 2020 at PBAC (Australia).
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2020; on this evidence the file is dormant.
7 distinct indication wordings are recorded for topotecan by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 17 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess topotecan, on 21 Jun 2006; PBAC (Australia) did not open a file until 2020 — an unusually long tail of 14.1 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 9 years in total.
Restriction is doing real work here: 4 of 13 decisive outcomes narrowed topotecan to a subgroup rather than accepting or refusing it outright, at NICE (England) and SMC (Scotland).
4 of the 7 agencies here assessed topotecan more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for topotecan.
The full ledger for topotecan reads 9 recommended, 4 restricted, 2 superseded and 1 deferred to NICE, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2020 | Metastatic ovarian cancer | The PBAC recommended the listing of a new form of topotecan, Topotecan Accord®, as an unre… | source |
| PHARMAC (New Zealand) | 14 Feb 2013 | Hospital listing | PTAC advice: Recommended for funding with no priority · decision reached | source |
| NICE (England) | 25 Nov 2009 | NICE TA184 | recommended (optimised) | source |
| SMC (Scotland) | 14 Apr 2009 | Monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) | accepted (restricted) | source |
| HAS (France) | 3 Sep 2008 | Listing (Transparency Committee) | ASMR IV | source |
12 further decisions for topotecan, across 5 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- docetaxel — same ATC class L01C — Antineoplastics
- paclitaxel — same ATC class L01C — Antineoplastics
- irinotecan — same ATC class L01C — Antineoplastics
- trabectedin — same ATC class L01C — Antineoplastics
- cabazitaxel — same ATC class L01C — Antineoplastics
- vinorelbine — same ATC class L01C — Antineoplastics
Coverage: 17 decisions for topotecan from 7 agencies, 2006 to 2020. Data to 7 Sep 2026. ATC class L01C — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.